Vanguard reports 4.49% stake in Rani Therapeutics
Vanguard Capital Management reported its holdings of Rani Therapeutics Holdings Inc common stock, beneficially owning 5,052,862 shares, representing 4.49% of the class as of June 30, 2026.
Rhea-AI Filing Summary
Vanguard Capital Management reported its holdings of Rani Therapeutics Holdings Inc common stock, beneficially owning 5,052,862 shares, representing 4.49% of the class as of June 30, 2026. These securities have CUSIP 753018100.
Vanguard has sole voting power over 489,877 shares and sole dispositive power over 5,052,862 shares, with no shared voting or dispositive power. The holdings include securities managed by Vanguard Capital Management LLC and certain affiliated entities and business divisions, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd.
The report notes that the position reflects securities held by Vanguard funds and client accounts over which these entities exercise voting and/or dispositive power. Interests of other persons in these securities are each below 5% of the class. The filing is signed by an authorized signatory, Head of Global Fund Administration, on July 31, 2026.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
dispositive power financial
sole voting power financial
percent of class financial
Investment Company Act of 1940 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which Vanguard entities are included in the Rani Therapeutics (RANI) ownership reported by Vanguard Capital Management?
Does any other single investor hold more than 5% of Rani Therapeutics (RANI) through Vanguard-managed accounts?
What type of Rani Therapeutics (RANI) security is covered and what is its CUSIP?
AI-generated analysis. How Rhea-AI works. Not financial advice.